Minerva Neurosciences (NERV) Net Cash Flow (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Net Cash Flow data on file, last reported at -$49.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1118.45% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (up 187.84% YoY), and the FY2025 full-year result was $60.9 million, up 411.7% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$49.6 million, down from $70.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $70.0 million in Q4 2025 and bottomed at -$49.6 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$4.4 million (2024), against an average of -$1.7 million.
• The widest annual swing landed in 2024, when Net Cash Flow plunged 5180.68%; it then soared 1454.52% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$4.1 million in 2022, then slumped by 45.2% to -$6.0 million in 2023, then increased by 13.76% to -$5.2 million in 2024, then jumped by 1454.52% to $70.0 million in 2025, then plunged by 170.89% to -$49.6 million in 2026.
• The last three Net Cash Flow figures came in at -$49.6 million (Q1 2026), $70.0 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.

Peer Comparison